Enhanced CD8+ CTL formation for Adoptive Cell Therapies
|
- Summary
- A method of generating functionally improved cytotoxic T lymphocytes (CTLs) ex vivo independent of CD4+ T helper cells for use in adoptive cell therapy (ACT). Inhibiting the tyrosine phosphatase PTPN2 achieves enhanced CTL formation and tumour killing.
- Technology Benefits
- - Enhanced existing cell therapy platforms - Compatible with the ex vivo reinvigoration of ‘tolerised’ T cells or tumour antigen specific CAR-T cells - 'Proof of Mechanism’ in vivo efficacy - Potential use in single agent and combination therapy applications
- Technology Application
- Adoptive cell transfer (CARs)
- Detailed Technology Description
- The team has generated data supporting PTPN2 inhibition as an approach to enhancing CTL formation and function. Genetic deficiency of PTPN2 enhances the generation and activation of effector/memory T cells ex vivo (Fig 1.) and enhances the activity of antigen specific CD8+ T cells in the context of adoptive transfer (Fig 2.). Furthermore, pharmacological inhibition of PTPN2 in human CD8+ T cells enhances TCR-mediated proliferation (Fig. 3). Current experiments are aimed at exploring methods of inhibiting PTPN2, using CAR-T cells specific for HER2, both in vitro and in vivo and in combination studies with anti-PD1 or anti-CTLA4 inhibitors.
- Type of Cooperation
- Licensing
- Application Date
- 10/06/2015 00:00:00
- Application No.
- AU2015274242
JA2016-572566
Others
- Others
- Monash seeks a partner to develop its technology within an ACT platform. The method has the potential to greatly improve CTL production and consequently, ACT therapy success.
- ID No.
- 2014-017
- Country/Region
- Australia
For more information, please click Here
